Erica Evans
About Erica Evans
Erica Evans serves as the Vice President of Biology and Translational Medicine at MOMA Therapeutics, a position she has held since 2020. She has previously held leadership roles at Blueprint Medicines and Celgene Avilomics Research, contributing significantly to the field of cancer research.
Work at MOMA Therapeutics
Erica Evans has served as Vice President of Biology and Translational Medicine at MOMA Therapeutics since 2020. In this role, she is responsible for overseeing the biological research and development processes that drive the company's therapeutic innovations. Her leadership contributes to advancing the understanding of disease mechanisms and the development of targeted therapies.
Previous Experience at Blueprint Medicines
Prior to her current position, Erica Evans worked at Blueprint Medicines as Vice President of Cancer Drivers from 2012 to 2019. During her tenure, she focused on the development of targeted therapies for cancer, contributing to the company's mission of delivering precision medicines to patients. Her experience in this role enhanced her expertise in oncology and translational medicine.
Career at Celgene Avilomics Research
Erica Evans was employed at Celgene Avilomics Research, formerly known as Avila Therapeutics, as a Principal Scientist from 2010 to 2012. In this capacity, she engaged in research aimed at discovering and developing innovative therapeutics. Her work contributed to the advancement of drug discovery processes within the organization.
Early Career at GPC Biotech
Erica Evans began her career at GPC Biotech, where she held the position of Scientist II from 2002 to 2007. In this role, she was involved in various research projects that focused on cancer therapies. Her early experience laid the foundation for her subsequent roles in the biotechnology and pharmaceutical industries.
Educational Background
While specific educational details are not provided, Erica Evans's extensive career in biology and translational medicine suggests a strong academic foundation in relevant scientific disciplines. Her professional trajectory indicates a commitment to advancing her knowledge and expertise in the field.